Edesa Biotech Inc. (EDSA)
NASDAQ: EDSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EDSA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $27.02M
- EPS (TTM)
- -$1.72
- Dividend yield
- None
- 52-week range
- 0.72 – 20.32
- Day range
- 1.97 – 2.18
- Volume / Avg
- 120.96K / 1.45M
- Beta
- —
- Shares outstanding
- 13.51M
- Next earnings
- Dec 11, 2026
52-week range
EDSA stock today
On Nov 20, EDSA ended the session at $2.00, shedding $0.175 (8.05%), versus the S&P 500's 3.70% decline. Trading was light, with 120.96K shares changing hands, about 8% of the average daily volume. Shares are 90.2% below their 52-week high of $20.32, set on May 1, 2026 and 177.8% above the 52-week low of $0.72, near the bottom of the past year's range.
EDSA is up 40.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 17.6%. Edesa Biotech has posted a net loss over the last twelve months (EPS of -$1.72), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Dec 11; analysts expect EPS of -$0.57.
Summary generated from market data by MetaCap's automated system. Methodology
About Edesa Biotech
Company profileEdesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Pardeep Nijhawan FRCPC, M.D.
- Headquarters
- Markham, ON
- Employees
- 17
- Website
- edesabiotech.com
Financial highlights
Full financialsEdesa Biotech reported a net loss of $7.2 million, compared with a loss of $6.2 million a year earlier.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $780.00K | $0 |
| Growth | — | — | — | — | -100.00% |
| Net income | $-7.19M | $-6.17M | $-8.37M | $-17.55M | $-13.34M |
| EPS (diluted) | — | — | — | — | $-1.10 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$16.33+716.50%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Dec 11, 2026
- EPS estimate
- $-0.57
- Last reported (Q3 2026)
- Aug 13, 2026
- EPS actual vs est.
- $-0.60 vs —
EDSA news
All EDSA news- Edesa Biotech, Inc. Announces EU Orphan Designation for ParidiprubartNasdaq
- Edesa Receives EU Orphan Drug Designation For ARDS Therapy ParidiprubartNasdaqEDSA, ET
- Edesa Biotech Granted Orphan Designation for Paridiprubart for the Treatment of ARDS by the European CommissionGlobeNewswire
- Edesa Biotech Partners With KYORIN In Japan Deal Worth Up To $140 Million Plus Royalties; Stock UpNasdaqEDSA, LEN.B
- Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in JapanGlobeNewswire
- Edesa Biotech to Present at Guggenheim Healthcare Innovation ConferenceGlobeNewswire
- Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo StudyGlobeNewswire
Edesa Biotech peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NSRXNasus Pharma Ltd. | 2.29 | -10.20% | $26.82M | vs EDSA |
| TELOTelomir Pharmaceuticals Inc. | 0.364 | -17.24% | $26.82M | vs EDSA |
| BCTXBriaCell Therapeutics Corp. | 3.06 | -3.32% | $26.72M | vs EDSA |
| PMNProMIS Neurosciences Inc. | 3.16 | -1.56% | $28.43M | vs EDSA |
| AYTUAytu BioPharma Inc. | 2.66 | 0.00% | $28.91M | vs EDSA |
| ATHEAlterity Therapeutics Limited ADR | 1.52 | -8.16% | $29.02M | vs EDSA |
| RNTXRein Therapeutics Inc. | 0.3369 | -8.38% | $29.06M | vs EDSA |
| NNVCNanoViricides Inc. | 1.14 | -2.56% | $29.13M | vs EDSA |
Indexes, lists and sector
Edesa Biotech stock FAQ
What is Edesa Biotech's stock price today?
EDSA last traded at $2.00 as of Nov 20, 4:00 PM EST, down 8.05% on the day. Prices are delayed at least 15 minutes.
Does Edesa Biotech pay a dividend?
No. Edesa Biotech does not currently pay a regular cash dividend.
When is Edesa Biotech's next earnings date?
Edesa Biotech is expected to report earnings on Friday, December 11, 2026. Analysts expect EPS of $-0.57.
Who is Edesa Biotech's CEO?
Dr. Pardeep Nijhawan FRCPC, M.D. is the chief executive officer of Edesa Biotech Inc., which has about 17 employees.
Has EDSA ever split its stock?
Yes. The most recent EDSA stock split was a 1-for-7 split on Oct 11, 2023, one of 4 splits on record.
What is the EDSA 52-week high?
The 52-week high for EDSA is $20.32 and the 52-week low is $0.72. The stock is currently 90.2% below its high.